The critical window hypothesis: Hormone exposures and cognitive outcomes after menopause

Hormones, Cognition and Dementia: State of The Art and Emergent Therapeutic Strategies

Volumn , Issue , 2009, Pages 32-44

  Henderson, Victor W ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84927024549     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511635700.005     Document Type: Chapter

References (78)

1. Petersen RC, Doody R, Kurz A, et al Current concepts in mild cognitive impairment. Arch Neurol. 2001; 58:1985-92.
2. Henderson VW. Hormone Therapy and the Brain: a Clinical Perspective on the Role of Estrogen. New York: Parthenon Publishing, 2000.
3. Burger HG. The endocrinology of the menopause. Maturitas. 1996; 23:129-36.
4. Edwards DP. Regulation of signal transduction pathways by estrogen and progesterone. Annu Rev Physiol. 2005; 67:335-76.
5. Behl C, Skutella T, Lezoualch F, et al. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol. 1997; 51:535-41.
6. Shughrue PJ, Scrimo PJ, Merchenthaler I. Estrogen binding and estrogen receptor characterization (ERa and ERb) in the cholinergic neurons of the rat basal forebrain. Neuroscience. 2000; 96: 41-9.
7. Luine V. Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp Neurol. 1985; 89:484-90.
8. Maki PM, Resnick SM. Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition. Neurobiol Aging. 2000; 21:373-83.
9. Shaywitz SE, Shaywitz BA, Pugh KR, et al. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA. 1999; 281:1197-202.
10. Joffe H, Hall JE, Gruber S, et al. Estrogen therapy selectively enhances prefrontal cognitive processes: a randomized, double-blind, placebo-controlled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women. Menopause. 2006; 13:411-22.
11. Petanceska SS, Nagy G, Frail D, Gandy S. Ovariectomy and 17b-estradiol modulate the levels of Alzheimer’samyloid b peptides in brain. Neurology. 2000; 54: 2212-17.
12. Zheng H, Xu H, Uljon SN, et al. Modulation of Ab peptides by estrogen in mouse models. J Neurochem. 2002; 80:191-6.
13. Alvarez-De-La-Rosa M, Silva I, Nilsen J, et al. Estradiol prevents neural tau hyperphosphorylation characteristic of Alzheimer’s disease. Ann N Y Acad Sci. 2005; 1052:210-24.
14. Carroll JC, Rosario ER, Chang L, et al. Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3x Tg-AD mice. J Neurosci. 2007; 27: 13357-65.
15. Stone DJ, Rozovsky I, Morgan TE, et al. Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro. Exp Neurol. 1997; 143:313-18.
16. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. JAMA. 1997; 278:1349-56.
17. Gibbs RB. Long-term treatment with estrogen and progesterone enhances acquisition of a spatial memory task by ovariectomized aged rats. Neurobiol Aging. 2000; 21:107-16.
18. Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer’s disease on older women: the Cache County study. JAMA. 2002; 288:2123-9.
19. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer’s disease. Arch Intern Med. 1996; 156:2213-17.
20. Tang M-X, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet. 1996; 348: 429-32.
21. Resnick SM, Henderson VW. Hormone therapy and risk of Alzheimer disease: a critical time. JAMA. 2002; 288:2170-2.
22. Brinton RD. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action. Ann NY Acad Sci. 2005; 1052:57-74.
23. Jezierski MK, Sohrabji F. Neurotrophin expression in the reproductively senescent forebrain is refractory to estrogen stimulation. Neurobiol Aging. 2001; 22:309-19.
24. Leranth C, Roth RH, Elswoth JD, et al. Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson’s disease and memory. J Neurosci. 2000; 20:8604-9
25. Silva I, Mello LEAM, Freymuller E, Haidar MA, Baracat EC. Onset of estrogen replacement has a critical effect on synaptic density of CA1 hippocampus in ovariectomized adult rats. Menopause. 2003; 10:406-11.
26. Suzuki S, Brown CM, Dela Cruz CD, et al. Timing of estrogen therapy after ovariectomy dictates the efficacy of its neuroprotective and antiinflammatory actions. Proc Natl Acad Sci USA. 2007; 104:6013-18.
27. Savonenko AV, Markowska AL. The cognitive effects of ovariectomy and estrogen replacement are modulated by aging. Neuroscience. 2003; 119:821-30.
28. Daniel JM, Hulst JL, Berbling JL. Estradiol replacement enhances working memory in middle-aged rats when initiated immediately after ovariectomy but not after a long-term period of ovarian hormone deprivation. Endocrinology. 2006; 147: 607-14.
29. Stampfer MJ. Cardiovascular disease and Alzheimer’s disease: common links. J Intern Med. 2006; 260:211-23.
30. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007; 69:2197-204.
31. Herrington DM, Espeland MA, Crouse JR, 3rd, et al. Estrogen replacement and brachial artery flow- mediated vasodilation in older women. Arterioscler Thromb Vasc Biol. 2001; 21:1955-61.
32. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001; 135:939-53.
33. Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med. 2003; 349: 535-45.
34. Clarkson TB. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause. 2007; 14: 373-84.
35. Umetani M, Domoto H, Gormley AK, et al. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat Med. 2007; 13:1185-92.
36. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007; 297:1465-77.
37. Sherwin BB, Tulandi T. “Add-back” estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri. J Clin Endocrinol Metab. 1996; 81:2545-9.
38. Resnick SM, Maki PM, Golski S, Kraut MA, Zonderman AB. Effects of estrogen replacement therapy on PET cerebral blood flow and neuropsychological performance. Horm Behav. 1998; 34:171-82.
39. Hogervorst E, Williams J, Budge M, Riedel W, Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience. 2000; 101:485-512.
40. Le Blanc ES, Janowsky J, Chan BKS, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA. 2001; 285:1489-99.
41. Brett KM, Chong Y. Hormone Replacement Therapy: Knowledge and Use in the United States. Hyattsville, MD: National Center for Health Statistics, 2001.
42. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer’s disease in women: randomized, double-blind, placebo-controlled trial. Neurology. 2000; 54:295-301.
43. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. JAMA. 2000; 283:1007-15.
44. Asthana S, Baker LD, Craft S, et al. High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology. 2001; 57:605-12.
45. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study. JAMA. 2004; 291:2947-58.
46. Rapp SR, Espeland MA, Shumaker SA, et al. The effect of estrogen with progestin treatment on global cognitive function in postmenopausal women: results from the Women’s Health Initiative Memory Study. JAMA. 2003; 289:2663-72.
47. Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: the Women’s Health Initiative Memory Study. JAMA. 2004; 291: 2959-68.
48. Henderson VW, Espeland MA, Hogan PE, et al. Prior use of hormone therapy and incident Alzheimer’s disease in the Women’s Health Initiative Memory Study. Neurology. 2007; 68(suppl. 1): A205.
49. Henderson VW. Hormone therapy and Alzheimer’s disease: benefit or harm? Expert Opin Pharmacother. 2004; 5:389-406.
50. Henderson VW. Estrogen-containing hormone therapy and Alzheimer’s disease risk: understanding discrepant inferences from observational and experimental research. Neuroscience. 2006; 138: 1031-9
51. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol. 1996; 143:971-8.
52. Henderson VW, Benke KS, Green RC, Cupples LA, Farrer LA. Postmenopausal hormone therapy and Alzheimer’s disease risk: interaction with age. J Neurol Neurosurg Psychiatry. 2005; 76:103-5.
53. Brenner DE, Kukull WA, Stergachis A, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer’s disease: a population-based case-control study. Am J Epidemiol. 1994; 140: 262-7.
54. Seshadri S, Zomberg GL, Derby LE, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer’s disease. Arch Neurol. 2001; 58:435-40.
55. Kang JH, Weuve J, Grodstein F. Postmenopausal hormone therapy and risk of cognitive decline in community-dwelling aging women. Neurology. 2004; 63:101-7.
56. Carlson MC, Zandi PP, Plassman BL, et al. Hormone replacement therapy and reduced cognitive decline in older women: the Cache County study. Neurology. 2001; 57:2210-16.
57. Henderson VW, Sherwin BB. Surgical versus natural menopause: cognitive issues. Menopause. 2007; 14:572-9.
58. Resnick SM, Maki PM, Rapp SR, et al. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab. 2006; 91:1802-10.
59. Grady D, Yaffe K, Kristof M, et al. Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/Progestin Replacement Study. Am J Med. 2002; 113:543-8.
60. Viscoli CM, Brass LM, Kernan WN, et al. Estrogen therapy and risk of cognitive decline: results from the Women’s Estrogen for Stroke Trial (WEST). Am J Obstet Gynecol. 2005; 192:387-93.
61. Almeida OP, Lautenschlager NT, Vasikaran S, et al. 20-week randomized controlled trial of estradiol replacement therapy for women aged 70 years and older: effect on mood, cognition and quality of life. Neurobiol Aging. 2006; 27:141-9.
62. Yaffe K, Vittinghoff E, Ensrud KE, et al. Effects of ultra-low-dose transdermal estradiol on cognition and health-related quality of life. Arch Neurol. 2006; 63:945-50.
63. Xu J, Bartoces M, Neale AV, et al. Natural history of menopause symptoms in primary care patients: a Metro Net study. J Am Board Fam Pract. 2005; 18:374-82.
64. Henderson VW, Dudley EC, Guthrie JR, Burger HG, Dennerstein L. Estrogen exposures and memory at midlife: a population-based study of women. Neurology. 2003; 60:1369-71.
65. Herlitz A, Thilers P, Habib R. Endogenous estrogen is not associated with cognitive performance before, during, or after menopause. Menopause. 2007; 14:425-31.
66. Luetters C, Huang MH, Seeman T, et al. Menopause transition stage and endogenous estradiol and follicle-stimulating hormone levels are not related to cognitive performance: cross-sectional results from the study of women’s health across the nation (SWAN). J Women’s Health. 2007; 16: 331-44.
67. Fuh J-L, Wang S-J, Lee S-J, Lu S-R, Juang K-D. A longitudinal study of cognition change during early menopausal transition in a rural community. Maturitas. 2006; 53:447-53.
68. Kok HS, Kuh D, Cooper R, et al. Cognitive function across the life course and the menopausal transition in a British birth cohort. Menopause. 2006; 13:19-27.
69. Maki PM, Gast MJ, Vieweg A, Burriss SW, Yaffe K. Hormone therapy in menopausal women with cognitive complaints: a randomized, double-blind trial. Neurology. 2007; 69:1322-30.
70. Woods NF, Mitchell ES, Adams C. Memory functioning among midlife women: observations from the Seattle Midlife Women’s Health Study. Menopause. 2000; 7:257-65.
71. Shaywitz SE, Naftolin F, Zelterman D, et al. Better oral reading and short-term memory in midlife, postmenopausal women taking estrogen. Menopause. 2003;10:420-6.
72. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology. 1992; 17:485-95.
73. Rocca WA, Bower JH, Ahlskog JE, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology. 2007; 69:1074-83.
74. MacLennan AH, Henderson VW, Paine BJ, et al. Hormone therapy, timing of initiation, and cognition in women aged older than 60 years: the REMEMBER pilot study. Menopause. 2006; 13:28-36
75. Karim R, Hodis HN, Stanczyk FZ, Lobo RA, Mack WJ. Relationship between serum levels of sex hormones and progression of subclinical atherosclerosis in postmenopausal women. J Clin Endocrinol Metab. 2008; 93:131-8
76. Bagger YZ, Tankó LB, Alexandersen P, Qin G, Christiansen C. Early postmenopausal hormone replacement therapy may prevent cognitive impairment later in life. Menopause. 2005;12: 12-17.
77. Toran-Allerand CD. Estrogen as treatment for Alzheimer disease [letter]. JAMA. 2000;284: 307-8.
78. Kritz-Silverstein D, Barrett-Connor E. Hysterectomy, oophorectomy, and cognitive function in older women. J Am Geriatr Soc. 2002; 50:55-61.